Business Wire

CGTN

14.3.2020 20:00:05 CET | Business Wire | Press release

Share
CGTN: Latest Data Shows Over 36,000 Patients Had Recovered in Wuhan

In central China’s Wuhan, the epicenter of the coronavirus outbreak, new COVID-19 cases have dropped to a single digit, with just four reported Friday, according to a video by CGTN.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200314005025/en/

See full video:https://news.cgtn.com/news/2020-03-14/Fight-to-Reunite-How-Wuhan-tackled-COVID-19-ORhUCzRIGs/index.html

The latest data shows that over 36,000 patients had recovered in Wuhan, accounting for over 70 percent of its total cases. The hardest-hit city in central China's Hubei Province is well on its way to recovery.

As more patients are discharged from hospital, all 14 temporary hospitals in the city have been closed this week.

These hospitals, converted from public facilities, provided timely treatment for patients with mild symptoms. They have received over 12,000 patients.

Such remarkable progress did not come easily. The swift mobilization of national medical resources played a key role in containing the epidemic.

To assist the fight in Hubei, a total of 42,000 medical personnel from across the country were dispatched to the province. Around 65,000 pieces of medical equipment including ventilators and ECMOs (artificial lungs) had been sent to Hubei by March 3.

Treatment plans such as respiratory support and plasma therapy were tested and implemented. Traditional Chinese Medicine helped alleviate the symptoms of many patients and shorten the duration of treatment.

Thanks to the measures it has taken, China has now passed the peak of the outbreak, a government spokesperson said Thursday.

Outside Hubei, businesses are gradually springing back to life. Over 95 percent of enterprises above designated size have resumed operation, said an official on Friday.

Dr. Bruce Aylward, team leader of the China-WHO joint mission on COVID-19 said replicating the success of China's counterattack elsewhere will require speed, money, imagination and political courage.

About CGTN

Headquartered in Beijing, CGTN operates on television and online as a multi-language and multi-platform media organization. It has an international team of professionals based in Nairobi, Washington D.C. and London.

Social Media:

https://www.facebook.com/ChinaGlobalTVNetwork/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AV Access Presents eShare W90: A 4K Wireless Conferencing System for Smarter Hybrid Meetings at ISE 2026 in Barcelona28.1.2026 09:00:00 CET | Press release

AV Access proudly announces its participation in ISE 2026, one of the world’s leading AV and systems integration exhibitions. From February 3-6 at the Fira de Barcelona, Gran Via, the company will showcase its latest solutions designed to improve collaboration, enhance entertainment, and boost workplace productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128178621/en/ The eShare W90 wireless presentation and conferencing system makes hybrid meetings more secure, more collaborative, and far easier to manage. At Booth 1F110, AV Access will highlight its flagship innovations, including the eShare W90 wireless conferencing system, the plug-and-play 4KIP200 HDMI over IP solution, and the complete iDock series of KVM docking stations—demonstrating its dedication to versatile, high-performance AV technology. Stream, Charge and Share with a Single USB-C Cable At the heart of the booth is the eShare W90 wireless presentat

SES Extends EGNOS GEO-1 Satellite Service to Power Precise Navigation Across Europe28.1.2026 08:50:00 CET | Press release

The agreement ensures Europe’s satellite-based augmentation continues enhancing navigation for aviation and other critical users and lowering emissions SES, a leading space solutions company, and the European Union Agency for the Space Programme (EUSPA) today announced an extension of the European Geostationary Navigation Overlay Service (EGNOS) GEO-1 satellite service agreement through 2030, with an option to extend until 2032, helping maintain high-precision navigation services for aviation and other critical users across Europe. By improving the accuracy and integrity of satellite positioning signals, EGNOS supports aircraft in landing in low-visibility conditions, as well as planning more efficient routes, reducing fuel burn and CO₂ emissions. At the core of the EGNOS service is Europe’s regional Satellite-Based Augmentation System (SBAS) that improves the accuracy and reliability of Global Navigation Satellite System (GNSS) signals, such as GPS. Beyond aviation, EGNOS supports mar

LTTS Secures Strategic Engineering and R&D Agreement from Global Automotive OEM28.1.2026 08:30:00 CET | Press release

Key win in LTTS’ Mobility Segment across multiple vehicle technology domains L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, announced that it has secured a significant multi-year engagement in its Mobility segment from a leading automotive OEM. The strategic win further strengthens LTTS’ long-standing partnership with the premium automotive manufacturer and underscores its growing role in supporting next-generation mobility engineering. The engagement encompasses advanced software, connectivity and digital engineering services across multiple vehicle technology domains. LTTS will draw on its global engineering expertise, strong domain knowledge and proven delivery frameworks to support the customer’s evolving product and technology roadmap. This win reinforces LTTS’ comprehensive mobility engineering capabilities, spanning embedded systems, digital platforms, verification and validation, cloud integration, cybersecurity, and

SFI Health™ EMEA Announces the Launch in Poland of Equazen® Forte, Marking a New Chapter in Cognitive Support for Young Adults and Adults28.1.2026 08:00:00 CET | Press release

Equazen® Forte represents a strategic evolution of the brand, extending its clinically researched omega-3 based cognitive support product formulation beyond children to young adults and adults through pharmacies across Poland. SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, today is pleased to announce the launch of Equazen® Forte in Poland, a new concentrated omega 3 product formulation to be added to the Equazen® range designed to support the normal cognitive performance for young adults and adults. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127646023/en/ Equazen® Forte: a key milestone in the brand’s long-term development strategy. Equazen® Forte represents a key milestone in the brand’s long-term development strategy. Traditionally recognized as a pediatric brain health expert, Equazen® is now evolving to support consumers across different life stages, addressing changi

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 07:07:00 CET | Press release

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye